Finance

Beta
Lists
AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$13.32
-6.92%
(-0.99) 1D
$13.29
-0.23% (-0.030)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMLX...
Open
$14.25
High
$14.47
Low
$12.96
Mkt. cap
1.48B
Avg. vol.
1.09M
Volume
1.74M
52-wk high
$18.60
52-wk low
$4.80
EPS
-$1.51
Beta
-0.16
Shares outstanding
111.19M
No. of employees
136
Open
$14.25
High
$14.47
Low
$12.96
Mkt. cap
1.48B
Avg. vol.
1.09M
Volume
1.74M
52-wk high
$18.60
52-wk low
$4.80
EPS
-$1.51
Beta
-0.16
Shares outstanding
111.19M
No. of employees
136
Analyst outlook
Analyst Ratings
Based on 7 analysts giving stock ratings to AMLX in the past 3 months
Strong Buy
Buy
7
Hold
0
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for AMLX in the last 3 months.
Highest
Current $13.32
$34.00 (+155.26%)
Average
$25.17 (+88.96%)
Lowest
$20.00 (+50.15%)
News stories
From sources across the web
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc
CEO-
Employees136
Founded2013
Headquarters-
SectorPharmaceutical industry
Websiteamylyx.com
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.37 / -$0.35
-4.98%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
27.22M
19.86M
21.21M
27.61M
Cost of revenue
27.22M
19.86M
21.21M
27.61M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.64M
16.17M
15.39M
16.17M
Operating expense
15.64M
16.17M
15.39M
16.17M
Total operating expenses
42.86M
36.03M
36.60M
43.78M
Operating income
-42.86M
-36.03M
-36.60M
-43.78M
Other non operating income
-
-
-6.23M
-
EBT including unusual items
-41.44M
-34.39M
-32.95M
-41.28M
EBT excluding unusual items
-41.44M
-34.39M
-38.48M
-41.28M
Income tax expense
-
-
46.00K
-
Effective tax rate
-
-
-0.14%
-
Other operating expenses
-
-
-
-
Net income
-41.44M
-34.39M
-33.00M
-41.28M
Net profit margin
-
-
-
-
Earnings per share
-0.46
-0.37
-0.30
-0.37
Interest and investment income
1.96M
1.82M
3.29M
2.57M
Interest expense
-
-
-
-
Net interest expenses
1.96M
1.82M
3.29M
2.57M
Depreciation and amortization charges
-
-
-
-
EBITDA
-42.72M
-35.91M
-36.50M
-43.68M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer